Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review

Lung cancer patients with brain and leptomeningeal metastases usually have poor prognosis. For those patients with EGFR mutations, osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the first choice of treatment. However, drug resistance to osimertinib frequently occurs; and to date...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hui, Wang, Yong, Wu, Huaguo, Zhou, Shizhen, Li, Shuo, Meng, Xiangji, Tao, Rongjie, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047901/
https://www.ncbi.nlm.nih.gov/pubmed/35494030
http://dx.doi.org/10.3389/fonc.2022.877279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047901/
https://www.ncbi.nlm.nih.gov/pubmed/35494030
http://dx.doi.org/10.3389/fonc.2022.877279

Ejemplares similares